Email this article 
An importance of matrix-metalloprotease determination in urine of patients with bladder cancer
- Authors: Tkachuk V.N.1, Al-Shukri A.S.1, Danilchenko D.I.1
-
Affiliations:
- Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation
- Issue: Vol 1, No 1 (2011)
- Pages: 30-32
- Section: Original articles
- URL: https://journals.eco-vector.com/uroved/article/view/57655
- DOI: https://doi.org/10.17816/uroved57655
- ID: 57655
Cite item
Open Access
Access granted
Abstract
The aim of this work is to estimate an influence of a depth and an extent of differentiation of neoplastic process on 2 and 9 matrix-metalloprotease levels in urine of patients with bladder cancer.
Patients and methods. 71 patients with bladder cancer have been investigated. 14 patients with chronic cystitis were included in an experimental group and 45 patients without bladder diseases were included in a control group, patients without urinary tract obstructions and infections were included in a control group. A level of metalloprotease was identified by a cimographic method.
Results. It has been proved that enzymes MMP-2 and MMP-9 of urine proteolysis are high sensitive markers of bladder cancer occurrence and their concentration depends on a depth of invasion and an extent of tumor differentiation, and shows a disease course prognosis.
Conclusion. It is reasonably to identify MMP-2 and MMP-9 of urine by the cimographic method for diagnostics and noninvasive determination of a depth of invasion and an extent of bladder cancer differentiation.
Keywords
Full Text
About the authors
Vladimir N. Tkachuk
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: tkachuk1@yandex.ru
Doctor of Medical Science, Professor, Honored Science Worker of Russian Federation, Department of Urology
Russian Federation, Saint PetersburgAdel S. Al-Shukri
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation
Email: ad330@mail.ru
Doctor of Medical Science, Professor, Department of Urology
Russian Federation, Saint PetersburgDmitriy I. Danilchenko
Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation
Email: al-shukri@mail.ru
doctor of medical science, urologist, hospital “Charite”
Russian Federation, Saint PetersburgReferences
- Аполихин О. И., Какорина Е. П., Сивков А. В. и др. Состояние урологической заболеваемости в Российской Федерации по данным официальной статистики // Урология. 2003. Т. 3. C. 3–9.
- Давыдов М. И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2004 году // Вестн. РОНЦ им. Блохина РАМН. 2006. Т. 17 (3). C. 52–89.
- Лопаткин Н. А., Даренков С. П., Чернышов И. В. и др. Диагностика и лечение рака мочевого пузыря // Урология. 2004. Т. 1. C. 12–17.
- Forsyth P. A., Wong H., Laing T. D. et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 are involved in different aspects of the pathophysiology of different aspects of malignant gliomas // Brit. J. Cancer. 1999. Vol. 79. P. 1828–1835.
- Kanayama H., Yokota K., Kurokawa Y. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer // Cancer. 1998. Vol. 82. P. 1359–1366.
- Sier C. F., Casetta G., Verheijen J. H. et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers // Clin. Cancer Res. 2000. Vol. 6. P. 2333–2340.
- Stetler-Stevenson W. G., Hewitt R., Corcoran М. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic //Semin Cancer Bil. 1996. Vol. 7. P. 1147–1154.
- Zucker S., Lysik R., Zarrabi H. et al. Plasma assay of gelatinase B: tissue inhibitor of metailoprotemase complexes in cancer // Cancer. 1995. Vol. 76. P. 700–708.
Supplementary files
